Type 2 Diabetes Drug, DPP-4 Inhibitor Linagliptin, is Clinically Effective for Long-Term Use, Cardiff University''s Thirty-Two Country Trial Suggests

Published: Jul 23, 2012

An extended trial of a drug for people with type 2 diabetes has confirmed that the oral DPP-4 inhibitor linagliptin is a safe and effective means of lowering glucose levels for up to 102 weeks, either on its own or in combination with other selected oral anti-diabetic medication. The 32-country study, published in the August issue of IJCP, the International Journal of Clinical Practice, followed 2,121 individuals who had taken part in four previous 24-week randomised, double-blind, placebo controlled trials, in order to monitor them for a further 78 weeks.

Back to news